| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Bayer Aktiengesellschaft (XETRA: BAYN)
BAYN Technical Analysis
5
| As on 28th Mar 2025 BAYN STOCK Price closed @ 22.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 29.89 & Strong Sell for SHORT-TERM with Stoploss of 36.13 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BAYNSTOCK Price
| Open | 22.60 | Change | Price | % |
| High | 23.04 | 1 Day | -0.10 | -0.44 |
| Low | 22.57 | 1 Week | -1.82 | -7.46 |
| Close | 22.57 | 1 Month | 1.19 | 5.57 |
| Volume | 2589394 | 1 Year | -19.58 | -46.45 |
| 52 Week High 42.52 | 52 Week Low 18.87 | ||||
XETRA Germany Most Active Stocks
| LHAR | 2.05 | -20.23% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BBVA | 5.00 | -2.72% |
| BVBA | 0.02 | -60.00% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| SNH | 0.16 | 6.67% |
| AMMN | 8500.00 | 1440578.00% |
| EOAN | 13.86 | 2.29% |
XETRA Germany Top Gainers Stocks
XETRA Germany Top Losers Stocks
| BAYN Daily Charts |
BAYN Intraday Charts |
Whats New @ Bazaartrend |
BAYN Free Analysis |
|
|
BAYN Important Levels Intraday
| RESISTANCE | 23.48 |
| RESISTANCE | 23.19 |
| RESISTANCE | 23.01 |
| RESISTANCE | 22.83 |
| SUPPORT | 22.31 |
| SUPPORT | 22.13 |
| SUPPORT | 21.95 |
| SUPPORT | 21.66 |
BAYN Forecast March 2025
| 4th UP Forecast | 33.88 |
| 3rd UP Forecast | 30.25 |
| 2nd UP Forecast | 28.01 |
| 1st UP Forecast | 25.77 |
| 1st DOWN Forecast | 19.37 |
| 2nd DOWN Forecast | 17.13 |
| 3rd DOWN Forecast | 14.89 |
| 4th DOWN Forecast | 11.26 |
BAYN Weekly Forecast
| 4th UP Forecast | 26.56 |
| 3rd UP Forecast | 25.28 |
| 2nd UP Forecast | 24.49 |
| 1st UP Forecast | 23.70 |
| 1st DOWN Forecast | 21.44 |
| 2nd DOWN Forecast | 20.65 |
| 3rd DOWN Forecast | 19.86 |
| 4th DOWN Forecast | 18.58 |
BAYN Forecast2025
| 4th UP Forecast | 69.15 |
| 3rd UP Forecast | 54.21 |
| 2nd UP Forecast | 44.98 |
| 1st UP Forecast | 35.74 |
| 1st DOWN Forecast | 9.4 |
| 2nd DOWN Forecast | 0.16 |
| 3rd DOWN Forecast | -9.07 |
| 4th DOWN Forecast | -24.01 |
Bayer Aktiengesellschaft ( XETRA Germany Symbol : BAYN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BAYN Business Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc. and Forschungszentrum Jülich GmbH; strategic research partnership with University of Oxford to develop novel gynecological therapies; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany. Address: Kaiser-Wilhelm-Allee 1, Leverkusen, Germany, 51368
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service